Australian Clinical Labs Ltd (AU:ACL) — Market Cap & Net Worth
Market Cap & Net Worth: Australian Clinical Labs Ltd (ACL)
Australian Clinical Labs Ltd (AU:ACL) has a market capitalization of $293.47 Million (AU$414.76 Million) as of June 17, 2026. Listed on the AU stock exchange, this Australia-based company holds position #15081 globally and #412 in its home market, demonstrating a 8.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Australian Clinical Labs Ltd's stock price AU$2.21 by its total outstanding shares 187672403 (187.67 Million). Review Australian Clinical Labs Ltd (ACL) financial obligations to assess the company's total debt and financial obligations.
Australian Clinical Labs Ltd Market Cap History: 2021 to 2026
Australian Clinical Labs Ltd's market capitalization history from 2021 to 2026. Data shows change from $676.46 Million to $293.47 Million (-4.61% CAGR).
Index Memberships
Australian Clinical Labs Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P/ASX 300
AXKO
|
$2.16 Trillion | 0.01% | #248 of 300 |
|
ASX Small Ordinaries
AXSO
|
$300.65 Billion | 0.10% | #156 of 200 |
Weight: Australian Clinical Labs Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Australian Clinical Labs Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Australian Clinical Labs Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.49x
Australian Clinical Labs Ltd's market cap is 0.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
11.26x
Australian Clinical Labs Ltd's market cap is 11.26 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $676.46 Million | $989.30 Million | $178.24 Million | 0.68x | 3.80x |
| 2021 | $676.46 Million | $641.31 Million | $60.37 Million | 1.05x | 11.20x |
| 2022 | $364.39 Million | $692.10 Million | $35.90 Million | 0.53x | 10.15x |
| 2022 | $364.39 Million | $989.30 Million | $178.24 Million | 0.37x | 2.04x |
| 2023 | $369.09 Million | $689.73 Million | $23.93 Million | 0.54x | 15.42x |
| 2023 | $369.09 Million | $692.10 Million | $35.90 Million | 0.53x | 10.28x |
| 2024 | $456.80 Million | $741.27 Million | $32.43 Million | 0.62x | 14.09x |
| 2024 | $456.80 Million | $689.73 Million | $23.93 Million | 0.66x | 19.09x |
| 2025 | $365.17 Million | $741.27 Million | $32.43 Million | 0.49x | 11.26x |
Competitor Companies of ACL by Market Capitalization
Companies near Australian Clinical Labs Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to Australian Clinical Labs Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.98 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #181 globally with a market cap of $127.92 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #622 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #662 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.98 Billion | $473.72 |
| #181 | Danaher Corporation | NYSE:DHR | $127.92 Billion | $181.10 |
| #622 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $570.00 |
| #662 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Australian Clinical Labs Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Australian Clinical Labs Ltd's market cap moved from $676.46 Million to $ 293.47 Million, with a yearly change of -4.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$293.47 Million | -19.64% |
| 2025 | AU$365.17 Million | -20.06% |
| 2024 | AU$456.80 Million | +23.76% |
| 2023 | AU$369.09 Million | +1.29% |
| 2022 | AU$364.39 Million | -46.13% |
| 2021 | AU$676.46 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Australian Clinical Labs Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $293.47 Million USD |
| MoneyControl | $293.47 Million USD |
| MarketWatch | $293.47 Million USD |
| marketcap.company | $293.47 Million USD |
| Reuters | $293.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Australian Clinical Labs Ltd
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veter… Read more